Trovagene Inc. (TROV) Trading Up 3.8%
Shares of Trovagene Inc. (NASDAQ:TROV) were up 3.8% during mid-day trading on Thursday . The stock traded as high as $4.80 and last traded at $4.67, with a volume of 238,007 shares changing hands. The stock had previously closed at $4.50.
A number of analysts have issued reports on TROV shares. Janney Montgomery Scott lowered shares of Trovagene from a “buy” rating to a “neutral” rating in a research note on Friday, March 11th. Cantor Fitzgerald reiterated a “buy” rating and set a $10.00 price target on shares of Trovagene in a research note on Friday, March 11th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $8.00 price target on shares of Trovagene in a research note on Saturday, March 12th. Maxim Group reiterated a “buy” rating on shares of Trovagene in a research note on Saturday, March 12th. Finally, Avondale Partners reiterated a “market perform” rating and set a $6.00 price target on shares of Trovagene in a research note on Tuesday, March 29th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Trovagene presently has a consensus rating of “Hold” and a consensus price target of $6.96.
The company’s market capitalization is $144.23 million. The company has a 50-day moving average price of $4.82 and a 200 day moving average price of $4.80.
Trovagene (NASDAQ:TROV) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.07. On average, analysts predict that Trovagene Inc. will post ($1.30) EPS for the current year.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.